Erlotinib versus chemotherapy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer (OPTIMAL, CTONG-0802): a multicentre, open-label, randomised, phase 3 studyCaicun Zhou, Changxuan You, Yi‐Long Wu et al.|The Lancet Oncology|2011Cited by 4.1k
DNA methyltransferase inhibitors combination therapy for the treatment of solid tumor: mechanism and clinical applicationChunhong Hu, Fang Wu, Xiaohan Liu et al.|Clinical Epigenetics|2021Cited by 253
Association between pretreatment emotional distress and immune checkpoint inhibitor response in non-small-cell lung cancerYue Zeng, Fang Wu, Sheng-Hao Shi et al.|Nature Medicine|2024Cited by 116
Genomic profiles and their associations with TMB, PD-L1 expression, and immune cell infiltration landscapes in synchronous multiple primary lung cancersChunhong Hu, Fang Wu, Lishu Zhao et al.|Journal for ImmunoTherapy of Cancer|2021Cited by 77
The key to immunotherapy: how to choose better therapeutic biomarkers for patients with non-small cell lung cancerYue Pan, Fang Wu, Yucheng Fu et al.|Biomarker Research|2022Cited by 57